Compound ID | 1735
Class: Antibody (monoclonal antibody [mAb])
Spectrum of activity: | Gram-positive |
Details of activity: | Active against B. anthracis |
Institute where first reported: | Human Genome Sciences (HGS) |
Year first mentioned: | 2009 |
Highest developmental phase: | Approved by FDA in 2012 |
Development status: | Approved |
External links: | |
Guide to Pharmacology: | raxibacumab |
Citations: |
|